SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to an earnings "double beat" and positive AI demand commentary, fueling optimism and sending shares higher after hours. The community is celebrating the results, anticipating further gains, and some speculate about government influence and potential short squeezes. Discussions include targets, the CEO's performance, and the broader implications for the semiconductor sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid speculation and conflicting reports about potential government equity stakes in quantum computing firms, driving volatility and high trading volume. The community is debating the validity and impact of the rumored deal, with some seeing it as a validation of the sector while others believe it's a pump and dump scheme. Broader discussions include the long-term potential of quantum computing and its significance in the global technology race.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its strategic partnership with Palantir to enhance enterprise AI capabilities and its potential role in the growing AI sector, particularly regarding data centers and fiber optic infrastructure. Community members are also anticipating upcoming earnings and speculating on potential acquisitions. The broader discussion revolves around Lumen's transformation and its position in the evolving tech landscape.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford ($F) is trending as investors react to potential tariff relief and strong Q3 sales figures, including a surge in EV sales, before the EV tax credit expires. Community members are discussing whether Ford can sustain this momentum, especially with a focus on management's plans and the potential for a breakout above the $12.50 resistance level. Some are also closely monitoring a news report regarding potential changes coming Monday.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber's stock is trending amid news of a collaboration with Nvidia to advance autonomous vehicle technology, sparking discussions about the company's strategic position and potential revenue streams in the evolving transportation sector; the community is analyzing the partnership's impact, especially in light of Uber's existing partnerships with EV manufacturers like Lucid and potential competition with Tesla. Some investors believe this could drive significant growth, while others express concern about immediate revenue impact and the stock's historical resistance to meaningful gains on news.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor (DECK) is experiencing share price volatility despite a recent earnings beat, leading to community discussion about potential reasons for the disconnect, including concerns about future guidance. Some traders point to significant call option activity, while others speculate on the impact of tariffs and broader retail sector trends. Despite strong brand performance with Hoka and UGG, investors are debating whether the current price represents a buying opportunity or reflects deeper concerns.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp ($NEM) is trending after posting strong quarterly earnings, exceeding analysts' estimates, which the community is calling a major beat. Bullish sentiment is growing as investors discuss cost-saving initiatives and rising gold prices potentially driving the stock higher. However, some traders are cautious, anticipating short-term pullbacks and profit-taking despite the positive results.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences ($VTYX) is trending due to recent Phase 2 trial results, sparking discussions around the drug's potential in treating obesity and cardiovascular risk factors. While some traders are optimistic about potential analyst upgrades and a possible buyout, others express concerns about a potential offering. Community members are actively debating entry and exit points, as well as speculating on future price movements and consolidation.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as investors discuss potential government contracts and insider trading after significant call option sweeps, specifically for the $27 strike price. Community members speculate about upcoming news related to rare earth minerals and uranium, driven by geopolitical tensions and a focus on domestic supply chains. While some traders express caution and highlight algorithmic trading patterns, bullish sentiment remains strong due to the company's strategic positioning in the sector.

BlackRock, Inc. engages in the provision of investment, advisory and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is trending as the community discusses institutional investment and potential short squeeze opportunities for a related stock, $BYND.  Traders are pointing to BlackRock's existing stake in $BYND, meme ETF inclusion, and upcoming earnings as potential catalysts. Some investors are also watching for a broader market momentum shift into BLK, highlighting its stability within the financial sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incannex Healthcare Inc. (IXHL) has experienced a 234% increase in retail chatter on Stocktwits over the past seven days, while message volumes have risen 193% over the past 30 days on the platform. Shares of the company drew investor attention on Wednesday morning as it declined nearly 10% at the opening bell.Incannex is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:574/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_9_16_43_AM_png_8958508111.webp" alt="IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="574" height="66"><figcaption>IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/why-is-incannex-healthcare-surging-today/chsHHZBRdjh">announced </a>positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The company stated that the trial results confirm statistically significant and clinically meaningful improvements across all key endpoints assessed, including the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group.Of patients receiving treatment, 27% achieved complete disease remission, which is five times higher than the placebo rate, the company said. Additionally, the firm is exploring strategic partnerships to accelerate development and broaden global access to PSX-001.The company’s other two clinical-stage product candidates, IHL-42X and IHL-675A, are in different stages of development. While IHL-42X has completed a mid-stage clinical trial in obstructive sleep apnoea, IHL-675A is currently in a mid-stage clinical development program for the treatment of inflammatory conditions such as Arthritis.Incannex also <a href="https://stocktwits.com/news-articles/markets/equity/incannex-stock-soars-after-board-authorizes-20-million-share-repurchase-program/chsZIp3RdK2">authorized</a> a $20 million share repurchase program in August. CEO Joel Latham had stated that the program reflects the company’s confidence in the strength of its pipelines and the opportunities ahead. “We believe the current market valuation does not accurately reflect the significant progress we have made across our clinical programs,” he said.A Stocktwits user, meanwhile, expressed hopes for a partnership or buyout announcement on the company’s next earnings announcement.<stembedurl>https://stocktwits.com/IKEGAI/message/629801176</stembedurl>Shares of the company slumped 71% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-health-care-stock-surges-pre-market-after-activist-hedge-fund-reportedly-seeks-board-revamp/chD1bdjR33W">Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Incannex Healthcare Stock Sees Retail Chatter Explode 234% Over Last Week

The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.

Equity

The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.


Incannex Healthcare Inc. (IXHL) on Tuesday announced positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The stock shot up nearly 15% in Tuesday’s pre-market session.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.incannex.com/news-releases/news-release-details/incannex-reports-positive-results-phase-2-clinical-trial-psx-001">said</a> that the results from the trial confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study, including on the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group. This difference was statistically significant and sustained across the 11-week follow-up period, the company said.Of patients receiving treatment, 27% achieved full disease remission, five times higher than placebo. Quality of life also improved by an average of 10.6 points on the Personal Wellbeing Index in the PSX-001 group versus 2.7 points for placebo. “Psi-GAD demonstrated a reduction in anxiety, improved mood, enhanced quality of life, and better day-to-day functioning. Importantly, the treatment effect was durable and observed across 11 weeks,” said Lou Barbato, Chief Medical Officer of Incannex.The company is now preparing to initiate a multi-jurisdiction mid-stage clinical trial. Incannex is also exploring strategic partnerships to accelerate development and broaden global access to PSX-001.Treatment with Psi-GAD was well tolerated across the study population, the company said. The majority of treatment-emergent adverse events (TEAEs) were transient, mild to moderate in nature, and consistent with the expected pharmacological effects of Psilocybin, the company said. It added that there were no signs of concerns often cited with psychedelic treatments, such as increased suicidality, psychosis, or prolonged psychological distress. However, one subject withdrew from the trial, Incannex said.&nbsp;IXHL stock is down by 65% this year and by 61% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-oral-drug-delivers-significant-weight-loss-in-late-stage-study/chsHtgtRdj7">Eli Lilly’s Oral Drug Delivers Significant Weight Loss In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Why Is Incannex Healthcare Stock Surging Today? 

The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.

Incannex Healthcare Inc. (IXHL) announced on Friday that its board of directors has authorized a share repurchase program for up to $20 million of the company’s outstanding shares of common stockShares of the company were up 23% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:573/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_11_04_37_AM_png_83c7c67ea2.webp" alt="IXHL's Sentiment Meter and Message Volume as of 11 a.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="573" height="60"><figcaption>IXHL's Sentiment Meter and Message Volume as of 11 a.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes that the stock will trade over $1 soon.<stembedurl>https://stocktwits.com/Uppy/message/626218079</stembedurl>The company said that it may repurchase shares of common stock through open market purchases, privately negotiated transactions, accelerated share repurchase arrangements, or other methods. The timing and amount of any repurchases will depend on market conditions, available capital resources, among other factors, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.incannex.com/news-releases/news-release-details/incannex-healthcare-authorizes-20-million-share-repurchase">added</a>.CEO Joel Latham said that the firm believes the current market valuation does not accurately reflect the significant progress it has made across its clinical programs. “This initiative allows us to act decisively, strengthen our capital management strategy, and potentially enhance long-term value creation for shareholders,” he added.Incannex has three clinical-stage product candidates. Its lead candidate, IHL-42X, an oral fixed-dose combination of Dronabinol and Acetazolamide, is designed for the treatment of obstructive sleep apnea. The other programs are in development for rheumatoid arthritis and generalized anxiety disorder.In July, the company said that it is well-positioned to advance its portfolio of drug candidates through the next stages of development with a cash balance of about $50 million.IXHL stock is down by 73% this year and by 68% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/macquarie-downgrades-li-auto-on-rising-competition-in-chinese-market/chsZ3xRRdKb">This Stock Just Got Downgraded By Macquarie On Rising Competition In Chinese Market – Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Pharma Stock Soared 23% Today But Is Still Down Over 70% In 2025 – Find Out More

The company’s CEO said that the current market valuation does not accurately reflect the significant progress the firm has made across its clinical programs.

Shares of Incannex Healthcare Inc. hit their highest levels in nearly two months on Wednesday after the company released updates about its lead candidate, IHL-42X, a once-daily oral treatment for obstructive sleep apnea (OSA).The company announced completion of patient dosing for the Phase 2 portion of the RePOSA Phase 2/3 trial on May 8 and expects to finish final follow-up assessments by May 17.&nbsp;Shares of Incannex surged 720% on May 14 to close at $0.70, with the stock rising another 24% to $0.87 in after-hours trading.The program's pharmacokinetic and safety profiles, and clinical knowledge will help progress upcoming development stages and regulatory discussions with the FDA.The FDA end-of-Phase II meeting will formulate regulatory approaches for a new drug application.The company started its Phase 3 preparations, which will enroll 440 patients across multiple U.S. trial sites. U.S. investigators and trial participants drove the decision to concentrate geographically.IHL-42X treats intermittent hypoxia, defined by repeated blood oxygen level decreases, and hypercapnia, which involves carbon dioxide accumulation in the blood from inadequate airflow during sleep.Patients receive a dual therapy of dronabinol and acetazolamide to achieve combined effects that lessen disease severity.The Australian Phase 2 trials revealed that the lowest dose achieved a 51% reduction in the Apnea-Hypopnea Index (AHI) on average.&nbsp;Subsequent studies reported progress in measuring hypoxic burden (HB), which shows a stronger link to cardiovascular outcomes compared to AHI measurements.The company pointed out that IHL-42X may be used as a broader treatment option than weight loss therapies because data reveals that 67% of OSA patients are not obese.&nbsp;It also announced initiation of early commercial engagement initiatives, which demonstrate increasing attention from prospective partners.&nbsp;Incannex has advanced multiple late-stage drug candidates, including IHL-675A targeting inflammatory conditions and PSX-001 for generalized anxiety disorder.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested the sharp move in Incannex was part of what they described as a broader wave of "penny bio pharma mania" unfolding in the market.<stembedurl>https://stocktwits.com/StockFlips/message/614689194</stembedurl>Meanwhile, another user expressed regret over missing the rally while driving and hoped the stock would climb again the next day.<stembedurl>https://stocktwits.com/Moodymoney/message/614690960</stembedurl>The stock has declined 65.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Incannex Surges 720% On Sleep Apnea Trial Progress: ‘Penny Bio Pharma Mania’ Lifts Retail Sentiment

The company completed patient dosing in its Phase 2/3 trial for IHL-42X, a once-daily oral treatment for obstructive sleep apnea. Retail enthusiasm surged as the company eyes FDA talks, Phase 3 rollout in the U.S., and early commercial interest.

Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies

Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies.
read more...

FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug...

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Up 113.1% in March

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 208,200...

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Appendix: Comparison of PsiGAD Treatments to Existing Registered Treatments for Anxiety

 Figure: meta-analysis(1) of psychotropic medications for GAD, as measured by the HAM-A; the best...

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology...

Is Incannex Healthcare (NASDAQ:IXHL) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IXHL News

IXHLIncannex Healthcare Limited - ADR